VOR NASDAQ
Vor Biopharma Inc.
1W: -0.2%
1M: -1.8%
3M: +11.0%
YTD: +29.2%
1Y: +321.3%
3Y: -83.7%
5Y: -96.1%
$14.33
-0.71 (-4.72%)
Weekly Expected Move ±8.8%
$12
$13
$15
$16
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$98.2M
52W Range3.3-65.8
Volume727,634
Avg Volume1,039,857
Beta1.75
Dividend—
Analyst Ratings
Company Info
CEOJean-Paul Kress
Employees159
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-05
Websitevorbio.com
100 Cambridgepark Drive
Cambridge, MA 02140
US
Cambridge, MA 02140
US
617 655 6580
About Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest News
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
Vor Biopharma (NASDAQ:VOR) Director Sells $2,604,415.50 in Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | S-Sale | 165,150 | $15.77 | 2026-04-22 |
| RA CAPITAL MANAGEMEN | S-Sale | 171,963 | $15.77 | 2026-04-20 |
| RA CAPITAL MANAGEMEN | S-Sale | 458,411 | $16.28 | 2026-04-17 |
| RA CAPITAL MANAGEMEN | S-Sale | 53,644 | $16.01 | 2026-04-15 |
| RA CAPITAL MANAGEMEN | S-Sale | 153,735 | $15.97 | 2026-04-14 |